DOCSLIB.ORG

Supplemental Table 1 Proteins Whose Content Is Significantly Modified in Hepatocytes by Aramchol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table 1 Proteins Whose Content Is Significantly Modified in Hepatocytes by Aramchol Supplemental table 1 Proteins whose content is significantly modified in hepatocytes by Aramchol. See text for experimental details Fold change Accession Protein name P value (Log2) achol/ctrl Fibrosis 6.29E- 0.13 P20152 Vimentin GN = Vim PE = 1 SV = 3 04 2.02E- 0.45 Q8BTM8 Filamin-A GN = Flna PE = 1 SV = 5 02 1.13E- 0.50 Q80X90 Filamin-B GN = Flnb PE = 1 SV = 3 02 Keratin type I cytoskeletal 18 GN = 4.89E- 0.78 P05784 Krt18 PE = 1 SV = 5 02 Translation RNA-binding protein 27 GN = Rbm27 1.08E- Q5SFM8 0.32 PE = 1 SV = 3 02 60S ribosomal protein L22-like 1 3.86E- Q9D7S7 0.42 GN = Rpl22l1 PE = 1 SV = 1 02 Trifunctional purine biosynthetic 2.33E- Q64737 protein adenosine-3 GN = Gart PE = 1 0.50 03 SV = 3 Eukaryotic translation initiation factor 3 3.10E- P23116 0.59 subunit A GN = Eif3a PE = 1 SV = 5 03 Glycine--tRNA ligase GN = Gars PE = 1 6.87E- Q9CZD3 0.63 SV = 1 03 Eukaryotic translation initiation factor 3 4.13E- Q8JZQ9 0.67 subunit B GN = Eif3b PE = 1 SV = 1 02 Elongation factor 1-gamma GN = Eef1g 2.47E- Q9D8N0 0.71 PE = 1 SV = 3 02 Q922B2 Aspartate--tRNA ligase cytoplasmic 2.02E- 0.72 GN = Dars PE = 1 SV = 2 02 Arginine--tRNA ligase cytoplasmic 1.47E- Q9D0I9 0.72 GN = Rars PE = 1 SV = 2 02 RNA-binding protein 25 GN = Rbm25 1.28E- B2RY56 1.92 PE = 1 SV = 2 02 Eukaryotic translation initiation factor 4 7.92E- Q80XI3 3.90 gamma 3 GN = Eif4g3 PE = 1 SV = 2 03 Lipid metabolism Prostaglandin reductase 1 GN = Ptgr1 4.55E- Q91YR9 0.42 PE = 1 SV = 2 02 3.09E- Q9DBG5 Perilipin-3 GN = Plin3 PE = 1 SV = 1 0.51 02 Acyl-CoA dehydrogenase family 3.98E- Q80XL6 1.21 member 11 GN = Acad11 PE = 1 SV = 2 02 Sterol 26-hydroxylase mitochondrial 2.98E- Q9DBG1 1.31 GN = Cyp27a1 PE = 1 SV = 1 02 Carnitine O-palmitoyltransferase 1 3.02E- P97742 1.32 liver isoform GN=Cpt1a PE=1 SV=4 02 Short-chain specific acyl-CoA 3.13E- Q07417 dehydrogenase mitochondrial GN = 1.36 02 Acads PE = 1 SV = 2 Hydroxymethylglutaryl-CoA synthase 2.19E- P54869 mitochondrial GN = Hmgcs2 PE = 1 SV 1.37 03 = 2 Trifunctional enzyme subunit beta 1.40E- Q99JY0 mitochondrial GN = Hadhb PE = 1 SV 1.38 02 = 1 Peroxisomal multifunctional enzyme 9.10E- P51660 1.39 type 2 GN = Hsd17b4 PE = 1 SV = 3 03 Delta(24)-sterol reductase GN = Dhcr24 2.69E- Q8VCH6 1.41 PE = 1 SV = 1 02 Very long-chain specific acyl-CoA 2.65E- P50544 dehydrogenase mitochondrial GN = 1.42 02 Acadvl PE = 1 SV = 3 Trifunctional enzyme subunit alpha 1.78E- Q8BMS1 mitochondrial GN = Hadha PE = 1 SV 1.42 02 = 1 Methylmalonyl-CoA mutase 1.21E- P16332 1.43 mitochondrial GN = Mut PE = 1 SV = 2 02 Peroxisomal acyl-coenzyme A oxidase 1 1.83E- Q9R0H0 1.43 GN = Acox1 PE = 1 SV = 5 02 Lipoamide acyltransferase component of branched-chain alpha-keto acid 4.62E- P53395 1.45 dehydrogenase complex mitochondrial 02 GN = Dbt PE = 1 SV = 2 Acyl-coenzyme A synthetase ACSM3 2.96E- Q3UNX5 mitochondrial GN = Acsm3 PE = 1 SV 1.46 02 = 2 Malate dehydrogenase mitochondrial 6.58E- P08249 1.46 GN = Mdh2 PE = 1 SV = 3 03 Long-chain specific acyl-CoA 4.07E- P51174 dehydrogenase mitochondrial GN = 1.47 02 Acadl PE = 1 SV = 2 Methylmalonate-semialdehyde dehydrogenase [acylating] 2.26E- Q9EQ20 1.47 mitochondrial GN = Aldh6a1 PE = 1 SV 04 = 1 D-beta-hydroxybutyrate 1.38E- Q80XN0 dehydrogenase mitochondrial GN = 1.50 02 Bdh1 PE = 1 SV = 2 Long-chain-fatty-acid--CoA ligase 1 1.94E- P41216 1.56 GN = Acsl1 PE = 1 SV = 2 02 Bile acyl-CoA synthetase GN = Slc27a5 2.76E- Q4LDG0 1.56 PE = 1 SV = 2 04 Acetyl-CoA acetyltransferase 2.82E- Q8QZT1 mitochondrial GN = Acat1 PE = 1 SV = 1.62 02 1 Cytochrome P450 2C70 GN = Cyp2c70 4.63E- Q91W64 1.63 PE = 1 SV = 2 02 Cytochrome P450 2D26 GN = Cyp2d26 2.50E- Q8CIM7 1.64 PE = 1 SV = 1 02 Apolipoprotein B-100 GN = Apob PE = 3.50E- E9Q414 1.65 1 SV = 1 02 Cytochrome b-c1 complex subunit 1 8.45E- Q9CZ13 mitochondrial GN = Uqcrc1 PE = 1 SV 1.68 04 = 2 1-acyl-sn-glycerol-3-phosphate 7.21E- Q8K3K7 acyltransferase beta GN = Agpat2 PE = 1.69 03 1 SV = 1 7-dehydrocholesterol reductase 4.41E- O88455 1.69 GN = Dhcr7 PE = 1 SV = 1 02 Long-chain-fatty-acid--CoA ligase 5 9.83E- Q8JZR0 1.70 GN = Acsl5 PE = 1 SV = 1 04 Very long-chain acyl-CoA synthetase 2.59E- O35488 1.72 GN = Slc27a2 PE = 1 SV = 2 03 Cytochrome P450 4V2 GN = Cyp4v2 PE 3.39E- Q9DBW0 1.73 = 1 SV = 1 02 Cytochrome P450 2D9 GN = Cyp2d9 1.44E- P11714 1.85 PE = 1 SV = 2 02 Acyl-CoA synthetase family member 2 1.39E- Q8VCW8 mitochondrial GN = Acsf2 PE = 1 SV = 1.85 04 1 Q9R1J0 Sterol-4-alpha-carboxylate 3- 3.84E- 1.92 dehydrogenase decarboxylating GN = 02 Nsdhl PE = 1 SV = 1 Acyl-CoA-binding domain-containing 1.82E- Q5XG73 2.08 protein 5 GN = Acbd5 PE = 1 SV = 1 02 Apolipoprotein E GN = Apoe PE = 1 SV 8.64E- P08226 2.59 = 2 03 Isovaleryl-CoA dehydrogenase 7.33E- Q9JHI5 2.92 mitochondrial GN = Ivd PE = 1 SV = 1 04 Sequestosome-1 GN = Sqstm1 PE = 1 2.90E- Q64337 5.01 SV = 1 02 1 Carbon metabolism 5-formyltetrahydrofolate cyclo-ligase 2.11E- Q9D110 0.44 GN = Mthfs PE = 2 SV = 2 02 Betaine--homocysteine S- 1.54E- O35490 methyltransferase 1 GN = Bhmt PE = 1 1.31 02 SV = 1 Sarcosine dehydrogenase 8.73E- Q99LB7 mitochondrial 1.33 04 GN = Sardh PE = 1 SV = 1 Dimethylglycine dehydrogenase 7.80E- Q9DBT9 mitochondrial GN = Dmgdh PE = 1 SV 1.36 03 = 1 Methyltransferase-like protein 7B 3.87E- Q9DD20 2.33 GN = Mettl7b PE = 1 SV = 2 02 Protein arginine N-methyltransferase 1 3.87E- Q9JIF0 2.62 GN = Prmt1 PE = 1 SV = 1 02 Carbohydrate metabolism Fructose-bisphosphate aldolase A GN = 2.59E- P05064 0.56 Aldoa PE = 1 SV = 2 02 6-phosphogluconate dehydrogenase 1.90E- Q9DCD0 0.64 decarboxylating GN = Pgd PE = 1 SV = 02 3 Aldo-keto reductase family 1 member 3.44E- Q8VC28 0.68 C13 GN = Akr1c13 PE = 1 SV = 2 02 Mannose-6-phosphate isomerase 1.49E- Q924M7 0.71 GN = Mpi PE = 1 SV = 1 02 Phosphoglycerate kinase 1 GN = Pgk1 1.31E- P09411 0.77 PE = 1 SV = 4 02 Phosphoglycerate mutase 1 GN = 5.04E- Q9DBJ1 0.77 Pgam1 PE = 1 SV = 3 03 UDP-glucuronosyltransferase 1-6 4.02E- Q64435 1.35 GN = Ugt1a6 PE = 1 SV = 1 02 Glycerol-3-phosphate dehydrogenase 4.87E- Q64521 mitochondrial GN = Gpd2 PE = 1 SV = 1.49 03 2 Urea cycle 4.35E- Q61176 Arginase-1 GN = Arg1 PE = 1 SV = 1 1.16 02 Carbamoyl-phosphate synthase 3.81E- Q8C196 [ammonia] mitochondrial GN = Cps1 1.29 02 PE = 1 SV = 2 2.62E- P25688 Uricase GN = Uox PE = 1 SV = 2 1.70 03 Ornithine aminotransferase 4.76E- P29758 mitochondrial 2.00 02 GN = Oat PE = 1 SV = 1 TCA cycle Glutamate dehydrogenase 1 1.18E- P26443 mitochondrial GN = Glud1 PE = 1 SV = 1.23 02 1 Serine--pyruvate aminotransferase 4.10E- O35423 1.38 mitochondrial GN = Agxt PE = 1 SV = 04 3 Aspartate aminotransferase 3.48E- P05202 mitochondrial GN = Got2 PE = 1 SV = 1.39 02 1 Succinate-semialdehyde 2.18E- Q8BWF0 dehydrogenase mitochondrial GN = 1.50 03 Aldh5a1 PE = 1 SV = 1 Succinate-CoA ligase (GDP-forming) 1.52E- Q9Z2I8 subunit beta mitochondrial GN = 1.55 03 Suclg2 PE = 1 SV = 3 Glutaminase liver isoform 1.23E- Q571F8 mitochondrial 1.59 02 GN = Gls2 PE = 1 SV = 2 Succinate-CoA ligase (ADP-forming) 5.11E- Q9Z2I9 subunit beta mitochondrial GN = 1.87 03 Sucla2 PE = 1 SV = 2 OxPhos & antioxidant response 4.84E- P24270 Catalase GN = Cat PE = 1 SV = 4 1.28 03 NADH-cytochrome b5 reductase 3 4.08E- Q9DCN2 1.32 GN = Cyb5r3 PE = 1 SV = 3 03 2.41E- P67778 Prohibitin GN = Phb PE = 1 SV = 1 1.35 02 ATP synthase subunit alpha 4.41E- Q03265 mitochondrial GN = Atp5a1 PE = 1 SV 1.38 03 = 1 ATP synthase subunit beta 1.68E- P56480 mitochondrial GN = Atp5b PE = 1 SV = 1.39 03 2 NADH-ubiquinone oxidoreductase 75 4.28E- Q91VD9 1.41 kDa subunit mitochondrial GN = 03 Ndufs1 PE = 1 SV = 2 Cytochrome b-c1 complex subunit 2 6.36E- Q9DB77 mitochondrial GN = Uqcrc2 PE = 1 SV 1.41 03 = 1 Electron transfer flavoprotein- ubiquinone oxidoreductase 3.06E- Q921G7 1.43 mitochondrial GN = Etfdh PE = 1 SV = 02 1 Glutathione S-transferase kappa 1 3.31E- Q9DCM2 1.43 GN = Gstk1 PE = 1 SV = 3 02 2.88E- O35129 Prohibitin-2 GN = Phb2 PE = 1 SV = 1 1.45 02 Cytochrome P450 2E1 GN = Cyp2e1 PE 2.20E- Q05421 1.51 = 1 SV = 1 02 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9 1.26E- Q9DC69 1.54 mitochondrial 02 GN = Ndufa9 PE = 1 SV = 2 Cytochrome P450 2F2 GN = Cyp2f2 PE 1.13E- P33267 1.57 = 1 SV = 1 02 NADH dehydrogenase [ubiquinone] 1.92E- Q91YT0 flavoprotein 1 mitochondrial GN = 1.58 03 Ndufv1 PE = 1 SV = 1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11 4.61E- O09111 1.89 mitochondrial GN = Ndufb11 PE = 1 02 SV = 2 Cytochrome P450 2A5 GN = Cyp2a5 PE 9.73E- P20852 4.29 = 2 SV = 1 03 .
Load more

Recommended publications
  • Mechanistic Studies on Medium Chain Acyl-Coa Dehydrogenase
    Acyl-CoA Dehydrogenases: Mechanistic studies on Medium Chain Acyl-CoA Dehydrogenase Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) an der Universität Konstanz (Fachbereich Biologie) vorgelegt von Vasile Robert Gradinaru Konstanz, im Juni 2005 Tag der mündlichen Prüfung : 9. November 2005 Referent: Prof. Dr. Sandro Ghisla Referent: Prof. Dr. Peter Macheroux Acknowledgements I am greatly indebted to my supervisor, Prof. Dr. Sandro Ghisla, for his advice and support. He has been an excellent supervisor providing insightful comments and constructive criticism throughout this PhD project. I would also like to thank my colleagues in the Universities of Konstanz and Iasi for their advice, encouragement and friendship, without which I would certainly not have completed this thesis. In particular, I would like to thank Prof. Dr. Richard Schowen, Prof. Dr. Peter Macheroux, Prof. Dr. Colin Thorpe, Prof. Dr. Jung-Ja. Kim, Prof. Dr. Tatiana Nicolaescu, Prof. Dr. Constantin Ciugureanu, Prof. Dr. Robert Bach, Dr. Olga Dmitrenko, Susanne Feindler-Boeckh, Gudrun Vogt, Elmi Leisner, Karl Janko, Lili Smau, Nasser Ibrahim, Phaneeswara Rao Kommoju, Sudarshan Rao Ande, Lakshminarayana Kaza, Cosmin Pocanschi, Paula Bulieris for their active interest during the course of this project. My gratitude also goes to Prof. Alexandru Cecal for encouraging me to embark on this PhD. I express my loving thanks to my wife Luiza whose love, support, patience and understanding made this work easier. Above all, I wish to express my sincerest gratitude to my parents, who made my studies possible and who have always encouraged me. This study was financiarlly supported by the Deutsche Forschungsgemeinschaft (Gh 2/6-4).
    [Show full text]
  • Inborn Errors of Metabolism Test Requisition
    LABORATORY OF GENETICS AND GENOMICS Mailing Address: For local courier service and/or inquiries, please contact 513-636-4474 • Fax: 513-636-4373 3333 Burnet Avenue, Room R1042 www.cincinnatichildrens.org/moleculargenetics • Email: [email protected] Cincinnati, OH 45229 INBORN ERRORS OF METABOLISM TEST REQUISITION All Information Must Be Completed Before Sample Can Be Processed PATIENT INFORMATION ETHNIC/RACIAL BACKGROUND (Choose All) Patient Name: ___________________ , ___________________ , ________ European American (White) African-American (Black) Last First MI Native American or Alaskan Asian-American Address: ____________________________________________________ Pacific Islander Ashkenazi Jewish ancestry ____________________________________________________ Latino-Hispanic _____________________________________________ Home Phone: ________________________________________________ (specify country/region of origin) MR# __________________ Date of Birth ________ / ________ / _______ Other ____________________________________________________ (specify country/region of origin) Gender: Male Female BILLING INFORMATION (Choose ONE method of payment) o REFERRING INSTITUTION o COMMERCIAL INSURANCE* Insurance can only be billed if requested at the time of service. Institution: ____________________________________________________ Policy Holder Name: _____________________________________________ Address: _____________________________________________________ Gender: ________________ Date of Birth ________ / ________ / _______
    [Show full text]
  • ACADS Rabbit Pab
    Leader in Biomolecular Solutions for Life Science ACADS Rabbit pAb Catalog No.: A0945 2 Publications Basic Information Background Catalog No. This gene encodes a tetrameric mitochondrial flavoprotein, which is a member of the A0945 acyl-CoA dehydrogenase family. This enzyme catalyzes the initial step of the mitochondrial fatty acid beta-oxidation pathway. Mutations in this gene have been Observed MW associated with short-chain acyl-CoA dehydrogenase (SCAD) deficiency. Alternative 44kDa splicing results in two variants which encode different isoforms. Calculated MW 44kDa Category Primary antibody Applications WB, IHC, IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 35 P16219 IHC 1:50 - 1:100 Immunogen 1:50 - 1:200 IF Recombinant fusion protein containing a sequence corresponding to amino acids 1-260 of human ACADS (NP_000008.1). Synonyms ACADS;ACAD3;SCAD Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using ACADS antibody (A0945) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 15s. Immunohistochemistry of paraffin- Immunohistochemistry of paraffin- Immunofluorescence analysis of U2OS embedded human liver cancer using embedded human liver damage using cells using ACADS antibody (A0945). Blue: ACADS antibody (A0945) at dilution of ACADS antibody (A0945) at dilution of DAPI for nuclear staining.
    [Show full text]
  • Positive Carrier Sample Report
    RESULTS RECIPIENT FEMALE MALE UNIVERSITY MEDICAL CENTER JANE MILLER N/A Attn: Dr. Paul Smith DOB: 11/11/1977 123 Main Street Ethnicity: Northern European City, CA 10231 Sample Type: OG-510 Saliva Phone: (800) 555-1212 Date of Collection: 02/06/2020 Fax: (800) 555-1212 Date Received: 02/16/2020 NPI: 4253506008 Date Tested: 02/16/2020 Report Date: 02/18/2020 Barcode: 55200006634190 Accession ID: FAKERQSCARFAF Indication: Screening for genetic disease carrier status Foresight® Carrier Screen POSITIVE: CARRIER ABOUT THIS TEST The Myriad Foresight Carrier Screen utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease. RESULTS SUMMARY Risk Details JANE MILLER Partner Panel Information Foresight Carrier Screen N/A Universal Panel Fundamental Plus Panel Fundamental Panel Fragile X Syndrome (176 conditions tested) POSITIVE: CARRIER CARRIER* The reproductive risk presented Smith‑Lemli‑Opitz Syndrome NM_001360.2(DHCR7):c. is based on a hypothetical 964-1G>C(aka IVS8-1G>C) pairing with a partner of the Reproductive Risk: 1 in 380 heterozygote same ethnic group. Carrier Inheritance: Autosomal Recessive testing should be considered. See "Next Steps". *Carriers generally do not experience symptoms. No disease-causing mutations were detected in any other gene tested. A complete list of all conditions tested can be found on page 6. Additional Findings Single Carrier Autosomal recessive additional findings CLINICAL NOTES NEXT STEPS • None • Carrier testing should be considered for the diseases specified above for the patient's partner, as both parents must be carriers before a child is at high risk of developing the disease.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Excluded Test List – As of 08/01/2016
    Excluded Test List – as of 08/01/2016 CPT As Gene Code 81161 DMD, dup_del 81200 ASPA, cv 81201 APC, fgs 81202 APC, kfv 81203 APC, dup_del 81205 BCKDHA, cv 81205 BCKDHB, cv 81209 BLM, 2281del6ins7 81220 CFTR, cv 81221 CFTR, kfv 81222 CFTR, dup_del 81223 CFTR, fgs 81224 CFTR, intron 8 poly-T 81228 Microarray, CNV 81229 Microarray, SNP 81240 F2, 20210G>A 81241 F5, Leiden (1691G>A) 81242 FANCC, cv 81243 FMR1 81244 FMR1, ma 81250 G6PC, cv 81251 GBA, cv 81252 GJB2, fgs 81253 GJB2, kfv 81254 GJB6, cv 81255 HEXA, cv 81257 HBA1_HBA2, cdel or v 81260 IKBKAP, cv 81271 SRY-FISH 81280 LQT, fgs 12 genes 81281 LQT, kfv 81282 LQT, dup_del 12 genes 81290 MCOLN1, cv 81291 MTHFR, cv 81302 MECP2, fgs 81304 MECP2, dup_del 81324 PMP22, dup_del 81325 PMP22, fgs 1, V14 81326 PMP22, kfv 81330 SMPD1, cv 81331 SNRPN_UBE3A, ma 81350 UGT1A1, cv 81400 ABCC8, F1388del 81400 ACADM, K304E 81400 AGTR1, 1166A>C 81400 BCKDHA, Y438n 81400 CCR5, del 81400 CLRN1, N48K 81400 DPYD, IVS14+1G>A 81400 FGFR1, P252R 81400 FGFR3, P250R 81400 FKTN, retro ins v 81400 GNE, M712T 81400 HPA-6 81400 HPA-9 81400 IVD, A282V 81400 LCT, 13910 C>T 81400 NEB, exon 55 81400 PCDH15, R245X 81400 SHOC2, S2G 81400 SLCO1B1, V174A 81400 SMN1, exon 7 del 81400 SRY, fgs 81400 TOR1A, var 81401 ABCC8, cv 81401 ACADM, cv 81401 ADRB2, cv 81401 AFF2, detect abn 81401 APOB, cv 81401 APOE, cv 81401 AR, alleles 81401 ATN1 81401 ATXN1 81401 ATXN10 81401 ATXN2 81401 ATXN3 81401 ATXN7 81401 ATXN8OS 81401 CACNA1A 2, V14 81401 CBS, cv 81401 CFH_ARMS2, cv 81401 CNBP 81401 CSTB 81401 CYP3A4, cv 81401 CYP3A5, cv 81401
    [Show full text]
  • And Detoxification (Benzola]Pyrene Quinones/Oxygen Radicals/NADPH-Cytochrome P-450 Reductase) PAUL L
    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 1696-1700, March 1984 Biochemistry Mutagenicity of quinones: Pathways of metabolic activation and detoxification (benzola]pyrene quinones/oxygen radicals/NADPH-cytochrome P-450 reductase) PAUL L. CHESIS*, DAVID E. LEVIN*, MARTYN T. SMITHt, LARS ERNSTERt, AND BRUCE N. AMES* Departments of *Biochemistry and tBiomedical and Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA 94720; and tDepartment of Biochemistry, Arrhenius Laboratory, University of Stockholm, S-10691 Stockholm, Sweden Contributed by Bruce N. Ames, December 12, 1983 ABSTRACT The mutagenicity of various quinones, a class nones might also be mutagenic, and we have tested this pos- of compounds widely distributed in nature, is demonstrated in sibility using the TA104 strain, which is sensitive to a wide the Salmonella TA104 tester strain. The metabolic pathways variety of oxidative mutagens (17). We have also attempted by which four quinones, menadione, benzo[alpyrene 3,6-qui- to characterize the pathways by which several different qui- none, 9,10-phenanthrenequinone, and danthron, caused mu- nones are metabolized and to study the potential mutagenic- tagenicity in this test system were investigated in detail as were ity of the metabolites and side products formed. We there- the detoxification pathways. The two-electron reduction of fore decided to investigate only those quinones that required these quinones by NAD(P)H-quinone oxidoreductase (DT-di- metabolic activation to exhibit mutagenicity. To limit the aphorase) was not mutagenic, whereas the one-electron reduc- scope of this project we also chose not to study quinones tion, catalyzed by NADPH-cytochrome P-450 reductase, was that possess reactive leaving groups.
    [Show full text]
  • Flavin Adenine Dinucleotide Status and the Effects of High-Dose Riboflavin Treatment in Short-Chain Acyl-Coa Dehydrogenase Deficiency
    0031-3998/10/6703-0304 Vol. 67, No. 3, 2010 PEDIATRIC RESEARCH Printed in U.S.A. Copyright © 2010 International Pediatric Research Foundation, Inc. Flavin Adenine Dinucleotide Status and the Effects of High-Dose Riboflavin Treatment in Short-Chain Acyl-CoA Dehydrogenase Deficiency BIANCA T. VAN MALDEGEM, MARINUS DURAN, RONALD J. A. WANDERS, HANS R. WATERHAM, AND FRITS A. WIJBURG Department of Pediatrics [B.T.M, F.A.W.] and Laboratory Genetic Metabolic Diseases [M.D., R.J.A.W., H.R.W.], University of Amsterdam, 1105 AZ Amsterdam, the Netherlands ABSTRACT: Short-chain acyl-CoA dehydrogenase deficiency most US states (15). In addition, potential treatment options (SCADD) is an inborn error, biochemically characterized by in- for SCADD have never been systematically studied. creased plasma butyrylcarnitine (C4-C) concentration and increased SCADD is caused by decreased activity of the first enzyme ethylmalonic acid (EMA) excretion and caused by rare mutations of the short-chain fatty acid ␤-oxidation spiral, which cata- and/or common gene variants in the SCAD encoding gene. Although lyzes the dehydrogenation of butyryl-CoA (C4-CoA). When its clinical relevance is not clear, SCADD is included in most US SCAD activity is impaired, C4-CoA will accumulate and is newborn screening programs. Riboflavin, the precursor of flavin subsequently converted into different metabolites including 1) adenine dinucleotide (FAD, cofactor), might be effective for treating the corresponding carnitine-ester, i.e. butyrylcarnitine (C4-C); SCADD. We assessed the FAD status and evaluated the effects of riboflavin treatment in a prospective open-label cohort study involv- 2) the corresponding glycine ester (butyrylglycine); 3) bu- ing 16 patients with SCADD, subdivided into mutation/mutation tyrate; and 4) ethylmalonic acid (EMA).
    [Show full text]
  • Expression in Escherichia Coli of Cytochrome C Reductase Activity from a Maize NADH:Nitrate Reductase Complementary DNA'
    Plant Physiol. (1992) 99, 693-699 Received for publication September 20, 1991 0032-0889/92/99/0693/07/$01 .00/0 Accepted December 11, 1991 Expression in Escherichia coli of Cytochrome c Reductase Activity from a Maize NADH:Nitrate Reductase Complementary DNA' Wilbur H. Campbell Phytotechnology Research Center and Department of Biological Sciences, Michigan Technological University, Houghton, Michigan 49931-1295 ABSTRACT the deduced amino acid sequences of NR to related mam- A cDNA clone was isolated from a maize (Zea mays L. cv malian protein sequences because of its similarity to the Mo- W64AxW183E) scutellum Xgtl 1 library using maize leaf pterin domain of sulfite oxidase, and the C-terminal region NADH:nitrate reductase Zmnrl cDNA clone as a hybridization of NR has sequence homology to NADH:Cyt b5 reductase, probe; it was designated Zmnr1S. ZmnrlS was shown to be an which is a FAD-containing enzyme (3, 22). In between the NADH:nitrate reductase clone by nucleotide sequencing and com- Mo-pterin and FAD domains, NR has similarity to mam- parison of its deduced amino acid sequence to Zmnrl. Zmnr1S, malian Cyt b5. This central Cyt b domain of NR is bridged to which is 1.8 kilobases in length and contains the code for both the other two domains on either side of it by highly variable the cytochrome b and flavin adenine dinucleotide domains of sequence regions that appear to be hinges (3). These hinge nitrate reductase, was cloned into the EcoRI site of the Esche- regions are probably exposed in native NR and susceptible to richia coli expression vector pET5b and expressed.
    [Show full text]
  • Cytochrome C, Cytochrome B5 and Electron Transfer
    Cytochrome c, cytochrome b5: electron transfer and new functions 1 Iron Protoporphyrin IX, heme b Heme a Prosthetic group Heme a is a form of heme found A flat and planar structure. In cytochromes a and a3. -. Itself Toxic O2 , H2O2 are formed. Insoluble 2 Covalent bonds Cytochrome c is a major player in membrane associated electron transport systems in bacteria and mitochondria. 3 Myoglobin, Hemoglobin His E7 Distal side Heme iron His F8 Proximal side Myoglobin has a strong affinity for oxygen Heme is located in the hydrophobic site. when it is in the lungs, and where the pressure is around 100 torr. When it reaches Heme Fe interacts with His. the tissues, where it's around 20 torr, the Coordination bond affinity for oxygen is still quite high. This makes myoglobin less efficient of an oxygen Propionates of heme interact with Arg. transporter than hemoglobin, which loses it's Ionic bond affinity for oxygen as the pressure goes down and releases the oxygen into the tissues. Heme is easily dissociated from the protein. Myoglobin's strong affinity for oxygen means that it keeps the oxygen binded to itself His (E7) is the oxygen binding site. instead of releasing it into the tissues. 4 Sickle cell anemia & malaria resistance In sickle cell hemoglobin (HbS) glutamic acid in position 6 (in beta chain) is mutated to valine. This change allows the deoxygenated form of the hemoglobin to stick to itself. 5 Figure 1. HO-1 Protects against Severe Malaria Using a mouse model for cerebral malaria, Ferreira et al. (2011) suggest a biochemical basis for the link between sickle cell disease and severe malaria.
    [Show full text]
  • Supplementary Material
    Supplementary material: Figure S1. Protein-Protein Interactions of the 127 Dysregulated proteins in brain tissues following IONP exposure. The graph was generated from STRING database. 125 nodes, 183 edges, 2.93 Average node degree, 0.411 Avg. local clustering coefficient, 122 Expected number of edges, PPI enrichment p-value 1.83e-07. 1 Figure S2. Protein-Protein Interactions of the 66 Dysregulated proteins in liver tissues following IONP exposure. The graph was generated from STRING database. 61 nodes, 103 edges, 3.38 Average node degree, 0.412 Avg. local clustering coefficient, 22 Expected number of edges, PPI enrichment p-value < 1.0e-16. 2 Figure S3. Protein-Protein Interactions of the 84 Dysregulated proteins in lung tissues following IONP exposure. The graph was generated from STRING database. 82 nodes, 125 edges, 3.05 Average node degree, 0.422 Avg. local clustering coefficient, 64 Expected number of edges, PPI enrichment p-value 1.07e-11. 3 Table S1. List of all dysregulated proteins in brain tissues following IONP exposure. A) Down regulated proteins and B) Upregulated proteins. Statistically significant iTRAQ ratios (p-value ratio and p-value sample≤0.05) for the 127 proteins that are dysregulated. A) Sequence Peptide Spectral P-Value P-Value Log 10 Accession Name Description Gene Coverage Ratio Count Count Ratio Sample Ratio % P00762 TRY1_RAT Anionic trypsin-1 Prss1 1 8 8.13 0.526 0.001 0.004 -0.279 P08592 A4_RAT Amyloid beta A4 protein App 1 2 1.17 0.546 0.010 0.004 -0.263 Q62696 DLG1_RAT Disks large homolog 1 Dlg1 1 1 1.32
    [Show full text]
  • Ferroptosis-Related Flavoproteins: Their Function and Stability
    International Journal of Molecular Sciences Review Ferroptosis-Related Flavoproteins: Their Function and Stability R. Martin Vabulas Charité-Universitätsmedizin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany; [email protected]; Tel.: +49-30-4505-28176 Abstract: Ferroptosis has been described recently as an iron-dependent cell death driven by peroxida- tion of membrane lipids. It is involved in the pathogenesis of a number of diverse diseases. From the other side, the induction of ferroptosis can be used to kill tumor cells as a novel therapeutic approach. Because of the broad clinical relevance, a comprehensive understanding of the ferroptosis-controlling protein network is necessary. Noteworthy, several proteins from this network are flavoenzymes. This review is an attempt to present the ferroptosis-related flavoproteins in light of their involvement in anti-ferroptotic and pro-ferroptotic roles. When available, the data on the structural stability of mutants and cofactor-free apoenzymes are discussed. The stability of the flavoproteins could be an important component of the cellular death processes. Keywords: flavoproteins; riboflavin; ferroptosis; lipid peroxidation; protein quality control 1. Introduction Human flavoproteome encompasses slightly more than one hundred enzymes that par- ticipate in a number of key metabolic pathways. The chemical versatility of flavoproteins relies on the associated cofactors, flavin mononucleotide (FMN) and flavin adenine dinu- cleotide (FAD). In humans, flavin cofactors are biosynthesized from a precursor riboflavin that has to be supplied with food. To underline its nutritional essentiality, riboflavin is called vitamin B2. In compliance with manifold cellular demands, flavoproteins have been accommo- Citation: Vabulas, R.M. dated to operate at different subcellular locations [1].
    [Show full text]